Ontology highlight
ABSTRACT:
SUBMITTER: Cohen S
PROVIDER: S-EPMC7496340 | biostudies-literature | 2020 Apr
REPOSITORIES: biostudies-literature
Cohen Stanley S Tuckwell Katie K Katsumoto Tamiko R TR Zhao Rui R Galanter Joshua J Lee Chin C Rae Julie J Toth Balazs B Ramamoorthi Nandhini N Hackney Jason A JA Berman Alberto A Damjanov Nemanja N Fedkov Dmytro D Jeka Slawomir S Chinn Leslie W LW Townsend Michael J MJ Morimoto Alyssa M AM Genovese Mark C MC
Arthritis & rheumatology (Hoboken, N.J.) 20200409
<h4>Objective</h4>To evaluate fenebrutinib, an oral and highly selective non-covalent inhibitor of Bruton's tyrosine kinase (BTK), in patients with active rheumatoid arthritis (RA).<h4>Methods</h4>Patients with RA and inadequate response to methotrexate (cohort 1, n=480) were randomized to fenebrutinib (50 mg once daily, 150 mg once daily, 200 mg twice daily), 40 mg adalimumab every other week, or placebo. Patients with RA and inadequate response to tumor necrosis factor inhibitors (cohort 2, n= ...[more]